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Abstract: Neonatal encephalopathy is a leading cause of morbidity and mortality worldwide. Al-
though therapeutic hypothermia (HT) is now standard practice in most neonatal intensive care units
in high resource settings, some infants still develop long-term adverse neurological sequelae. In low
resource settings, HT may not be safe or efficacious. Therefore, additional neuroprotective inter-
ventions are urgently needed. Melatonin’s diverse neuroprotective properties include antioxidant,
anti-inflammatory, and anti-apoptotic effects. Its strong safety profile and compelling preclinical data
suggests that melatonin is a promising agent to improve the outcomes of infants with NE. Over the
past decade, the safety and efficacy of melatonin to augment HT has been studied in the neonatal
piglet model of perinatal asphyxia. From this model, we have observed that the neuroprotective
effects of melatonin are time-critical and dose dependent. Therapeutic melatonin levels are likely to
be 15–30 mg/L and for optimal effect, these need to be achieved within the first 2–3 h after birth. This
review summarises the neuroprotective properties of melatonin, the key findings from the piglet and
other animal studies to date, and the challenges we face to translate melatonin from bench to bedside.
Keywords: neonatal encephalopathy; melatonin; neuroprotection; therapeutic hypothermia;
hypoxia-ischaemia
1. Introduction
Intrapartum hypoxic-ischemic (HI) events, resulting in neonatal encephalopathy (NE),
lead to significant neonatal mortality and morbidity worldwide. In 2010, an estimated
1.15 million babies developed NE globally, with an incidence of 8.5 per 1000 live births,
and almost 45% of infants with NE either died or developed moderate-severe neurodevel-
opmental impairment [1]. Furthermore, over the last 20 years, the global burden of disease
resulting from NE on childhood disability has increased by 35% as a result of improved
survival [2].
In high resource settings, the reported incidence of brain injury, secondary to HI, is
between 1.5 and 3.5 per 1000 live births [3–5]. Therapeutic hypothermia (HT), reducing
the core temperature of at-risk infants to 33.5 ◦C for 72 h, has become standard care
for moderate-severe NE following suspected HI in high resource settings. Whilst HT is
associated with a relative risk reduction of 25% in the composite outcome of death or major
disability and a number needed to treat of 7–9, 46% of infants still developed adverse
outcomes in clinical trials [6]. HT has expanded over the last decade to become an integral
part of neonatal neurocritical care, however improvement in outcomes is modest [7,8].
Whilst mortality rates have reduced by more than half (10.9% in 2014–2016) since clinical
trials [9], the rate of cerebral palsy remains at 19% [7,8] and even in its absence, 34%
of children still develop neurocognitive and psychological impairment that may impact
school performance [10]. Diffusion-weighted magnetic resonance imaging in school-aged
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children without cerebral palsy who were cooled at birth showed widespread defects in the
white matter microstructure, with disruption in brain network connectivity over regions
affecting visuo-spatial processing and attention [11]. Further neuroprotective interventions
are needed; in preclinical [12–14] and clinical studies [7], attempts to exploit HT effects
further, by increasing the depth and duration suggest that the current protocol of 72 h
cooling to 33.5 ◦C is optimal [15]. Therefore, adjunct therapies to augment HT hold the
greatest promise to improve outcomes in babies with NE.
The burden of NE secondary to intrapartum events is disproportionately higher
amongst low- and middle-income countries (LMIC). In particular, sub-Saharan Africa
and Southeast Asia account for more than 85% of all NE cases worldwide with regional
estimates as high as 14.9 per 1000 live births [1]. Globally, over 95% of neonatal deaths and
neurodevelopmental impairment occur in these regions where therapies are limited. In a
retrospective cohort study in Uganda, one third of infants with NE died in the neonatal
period, and of the survivors, a third developed neurodevelopmental impairment [16]. The
feasibility, safety, and efficacy of HT in LMIC remains uncertain. A systematic review of
seven clinical trials using various cooling devices including gel packs, water bottles, and
cooled water circuits showed no treatment benefit in reducing mortality associated with
NE [17]. Data for short-term and longer-term neurodevelopmental outcomes were limited.
The authors were unable to conclude whether the lack of apparent treatment effects were
attributed to a genuine lack of biological efficacy, related to the methodological weakness
in study designs, low-level technology and core temperature instability, or suboptimal
supportive care. The findings from the Hypothermia for Encephalopathy in Low and
Middle-Income Countries (HELIX) study, a large multicentre, randomised controlled HT
trial in south-east Asia [18] are concerning. In parallel to improving access to skilled birth
attendants, good quality, timely antepartum care, and the delivery of neonatal resuscitation
training programmes [19], there is an urgent unmet need to establish safe and effective
therapies for babies with NE in LMIC.
Melatonin (N-acetyl-5-methoxytryptamine), an indolamine hormone has become one
of the most promising neuroprotective agents for NE over the last 20 years. Its strong safety
profile, ability to cross the blood brain barrier and its diverse pleiotropic properties has
led to a large number of preclinical animal studies supporting its neuroprotective efficacy
in reducing brain injury [20]. Whilst the preclinical data is compelling, clinical studies
in infants with NE are limited [21]. Over the last decade, we have assessed the safety
and therapeutic potential of melatonin to complement HT in an established, large animal
piglet model of perinatal HI. The brain of the piglet, both in size and structure more closely
resembles the human infant than smaller animal models [22]. The weight and size of the
piglet allows standard neonatal intensive care procedures and protocols to be followed.
Cerebral metabolic changes in infants can be replicated in this model [23], ensuring the
translational relevance of these studies to the clinical setting. The newborn piglet model also
offers the opportunity to assess in-vivo, the pharmacokinetic, physiological and systemic
effects of therapeutic agents, thereby evaluating their safety, which is essential prior to
clinical studies in babies.
This review summarises the main neuroprotective actions of melatonin, discusses the
key findings from the University College London (UCL) neonatal piglet model of perinatal
asphyxia, and explores the challenges of moving melatonin along the translational pipeline
from bench to bedside to reduce the lifelong impact of NE.
2. The Neuroprotective Action of Melatonin for Neonatal Encephalopathy
In utero, the major source of melatonin in the developing fetus is primarily maternal.
Melatonin synthesis in the pineal gland occurs in a diurnal pattern, synchronised to the
light-dark cycle, reaching peak levels between 02:00 and 04:00. In response to darkness,
melatonin production is triggered in the pineolycytes via a complex, autonomic neural
pathway involving specialised melanopsin-containing retinal ganglion cells, the retinohy-
pothalamic tract and the supra-chiasmatic nucleus (our biological clock) [24]. In pregnancy,
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melatonin is also synthesised at high levels by placental trophoblast cells and production
gradually increases, particularly in the third trimester [25,26], to reach peak nocturnal
levels at term [27]. Maternal melatonin readily crosses the placenta and likely drives the
circadian melatonin levels we observe in the developing fetus [28,29]. Whilst the pineal
gland develops early in embryonic life, the gland continues to grow in the first 2 years
of life [30]. Following birth, the circadian rhythm of melatonin disappears and a period
of transient melatonin deficiency ensues [31,32]. In neonatal rodents, melatonin declines
rapidly in the first week of life [33]. The re-emergence of the circadian synthesis of mela-
tonin in term infants is not observed until after 3 months of age [29,31]. The term newborn
therefore has a period of relative melatonin deficiency; this deficiency might be a potential
target for supplementary melatonin as a potent therapy for NE. Melatonin deficiency has
been reported in intrauterine growth restriction [34] and prematurity [32], which are other
potential patient groups where melatonin supplementation may be beneficial. Interestingly,
Tauman et al. (2002) observed significantly lower levels of melatonin in the first weeks
of life in infants with delayed psychomotor development [35]. In this review, we focus
on melatonin as an acute therapy in the early hours and days after birth in term babies
with NE.
2.1. Evolution of Brain Injury
The evolution of brain injury in the first hours to days following HI occurs predictably
over several phases, described elegantly with phosphorus (31P) and proton (1H) magnetic
resonance spectroscopy (MRS) in newborn infants [36–39] and piglets [40,41] (Figure 1).
Two seminal studies by Lorek et al. (1994) [40] and Penrice et al. (1997) [41] reproduced the
sequence of events observed in newborn infants [36,37] after birth asphyxia in newborn
piglets. The acute period of HI, termed the primary insult, is characterized by energy
depletion, with a fall in [PCr]/[Pi] and [NTP]/[EPP], coinciding with a rise in Lactate to
N-acetyl aspartate (Lac/NAA) peak ratio [41]. The metabolite changes are also associated
with a fall in cerebral pH, presumed related to lactate production secondary to anaerobic
metabolism [40]. Following resuscitation, a period of metabolic recovery subsequently
ensues, where 31P metabolites and Lac/NAA return to baseline [40,41]. This latent phase
lasts around 1–6 h (but may be longer), and is the critical window of intervention for HT.
Following this period, a subsequent wave of energy failure lasting 24–48 h can be observed,
described as secondary energy failure. On MRS, [NTP]/[EPP] falls and Lac/NAA rises
despite adequate oxygenation, normal blood gas values and blood pressure [40,41]. The
deterioration in cerebral energetics progresses further in some animals, as seen in newborn
babies, whereas recovery was observed in some. The degree of secondary energy failure
relates to the severity of energy depletion during the primary insult [40] and correlates with
subsequent brain growth [42,43] and neurodevelopmental outcome [36,44]. The tertiary
phase of injury follows, spanning weeks to years after the initial insult and characterized
by persisting neuroinflammation, excitotoxity, and endogenous neuro-regeneration and
repair [45]. The ability to assess changes in cerebral energy metabolism using MRS and its
strong association with adverse neurodevelopmental outcomes in infants has led to interest
in its use as a surrogate biomarker for NE. Following recent refinement in spectral process-
ing, 1H MRS Lac/NAA peak ratio remains the most robust and accurate biomarker of early
childhood outcomes in infants who are cooled [44]. Lac/NAA peak ratio is therefore one
of the most important of the outcome measures in our translational model [46].
The detailed cellular and molecular mechanisms, leading to neuronal cell death and
brain injury are complex and beyond the scope of this short review but are addressed by
Wassink et al. (2014) [47], Gunn and Thoresen (2019) [48] and Greco et al. (2020) [49]. In
this review, we will explore the key mechanisms of injury relevant to the neuroprotective
action of melatonin (Figures 1 and 2). Hassell et al. (2013) [50] and Tarocco et al. (2019) [51]
also provide detailed review of the role of melatonin in neuroprotection for the newborn.
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2.2. Oxidative Stress 
The newborn brain is particularly vulnerable to oxidative stress compared to adults 
[52]. Reactive oxygen species (ROS) and other free radicals are formed early following HI 
[53,54]. During the primary insult, metabolites required for aerobic respiration are de-
pleted leading to reduced ATP production and the failure of the Na+/K+ pump required to 
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depolarisation leading to sodium, calcium, and water influx cause not only cytotoxic oe-
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Figure 1. The Evolution of Brain Injury, Pathophysiology and the Neuroprotective Action of Melatonin. Characteristic
phases (primary, latent, secondary and tertiary) of brain injury occurs following hypoxia-ischemia. These phases can be
measured using proton (1H) and phosphorus magnetic resonance spectroscopy. After the primary insult and a period
of recovery in the latent phase, secondary energy failure occurs (characterised by a secondary rise in Lactate to N-acetyl
aspartate (Lac/NAA) peak ratio on 1H MRS) in parallel with the neurotoxic cascades of cellular injury. The pathological
processes are multifactorial—including oxidative stress, activation of cell d ath pathways, neuro-inflammation, and
mitochondrial failure. The neuroprotective ction of m latonin is diverse. To harness its strong antioxidant properties,
supra-physiological melatonin levels (15–30 mg/L) are needed early in the neurotoxic cascade. Complementary therapies
including stem cells and erythropoietin targeting the tertiary phase of injury may further improve outcomes in combination
with melatonin for infants with NE.
2.2. Oxidative Stress
The newborn brain is particularly vulnerable to oxidative stress compared to adults [52].
Reactive oxygen species (ROS) and other free radicals are formed early following HI [53,54].
During the primary insult, metabolites required for aerobic respiration are depleted leading
to reduced ATP production and the failure of the Na+/K+ pump required to maintain the
neuronal membrane resting potential and osmotic equilibrium. Membrane depolarisation
leading to sodium, calcium, and water influx cause not only cytotoxic oedema, but excito-
toxicity through excess release of glutamate into synaptic clefts [47]. Glutamate binds to
NMDA receptors, leading to influx of Ca2+ into cells, activating nitric oxide synthase (NOS)
and subsequent generation of nitric oxide (•NO) free radicals. The mitochondria are the
main source of ROS (O2•−) generated, even under normal circumstances during oxidative
phosphorylation. These are cleared by antioxidant enzymes such as superoxide dismutase
and glutathione peroxidase. In HI conditions and during the re-oxygenation, reperfusion
phase of injury, the antioxidant system is overwhelmed, leading to a release of iron and per-
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oxide (•OH) ions which further contribute to oxidative damage [55]. •NO diffuses readily
and combines with O2•− to generate highly destructive peroxynitrite (ONOO−), leading
to lipid peroxidation in cell membranes, alteration of protein structure and function, and
DNA damage [47,49,55]. The accumulation of ROS plays a central role in mitochondrial
dysfunction, a hallmark in secondary energy failure [56]; oxidation of ETC complexes and
cardiolipin peroxidation of the mitochondrial membrane result in uncoupling of oxidative
phosphorylation, further ROS accumulation and failure to generate ATP. Ultimately, oxida-
tive stress leads to the activation of cell death pathways, amplification of mitochondrial
dysfunction and failure, further excitotoxicity, and neuro-inflammation contributing to the
detrimental neurotoxic cascade [47,49,52]. Agents targeting the oxidative stress pathways,
such as NOS inhibitors, have been exploited as neuroprotective interventions in animal
studies of HI with variable success [57].
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Figure 2. Melatonin and the Molecular Mechanisms of Action. (1) Melatonin and its metabolites; 3-hydroxymelatonin
(3OHM), N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK) form a potent
free radical scavenging artillery that removes reactive oxygen species (ROS) and other free radicals produced follow-
ing hypoxia-ischaemia. (2) Melatonin inhibits pro-apoptotic proteins (BAX), prevents the opening of the mitochon-
drial permeability transition pore and inhibits the poly(ADP-ribose) polymerase (PARP)-dependent cell death pathway.
(3) Melatonin exhibits anti-i fla atory properti s through the inhibition of itrogen oxide synthase and Toll-lik receptor
4 (TLR4) expression thereby suppressing inflamma ory cytokine and chemokine producti n. (4) Melatonin also acts through
receptors (MT1, MT2, MT3) to regulate a diverse range of downstream targets contributing to neuroprotection.
One of the remarkable neuroprotective actions of melatonin a d its metabolites is
its powerful and diverse antioxidant properties. Treatment with melatonin in animal
studies have shown association with reduction in •NO production [58] and in lipid perox-
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idation [59–62]. In an elegant study by Miller and colleagues (2005) [54], real-time •OH
production was measured in the grey and white matter of fetal sheep following umbilical
cord occlusion. Maternal administration of melatonin prior to HI ameliorated •OH efflux
in the grey matter during primary and secondary energy failure and was associated with a
reduction in lipid peroxidation on immunohistochemistry. Melatonin acts both directly,
via its non-receptor mediated action as a potent free-radical scavenger and indirectly,
to regulate the antioxidant defence system, promote synthesis of antioxidant enzymes,
inactivate NOS, and stabilize complex I of the ETC to reduce ROS leakage [63,64]. The
concept of the melatonin free-radical scavenger cascade has been adopted to describe the
highly effective sequential interaction between free radicals, melatonin, and its metabo-
lites [64]. Each melatonin molecule has the potential to scavenge up to 10 reaction oxygen
or nitrogen species [64]. Melatonin is metabolised into 3-hydroxymelatonin (3OHM), N1-
acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine
(AMK) (Figure 2); computational modelling has shown that each have highly effective free
radical scavenging capacity [65].
2.3. Cell Death
The mechanisms of neurodegeneration following HI is complex and have not been
fully elucidated. Cell death likely manifests as a continuum between apoptosis and necro-
sis as observed in animal studies [66,67]. Our understanding of cell death has expanded
beyond the traditional concepts of apoptosis, necrosis, and autophagy; the updated clas-
sification of cell death places a greater emphasis on molecular mechanisms rather than
morphology [68]. Following HI, both the death-receptor mediated “extrinsic”, and the
cytosolic, pro-apoptotic protein mediated “intrinsic” apoptotic pathways are activated. To-
gether, these pathways lead to the interaction between the pro-apoptotic proteins, Bax and
Bak, which forms mitochondrial membrane pores, resulting in the leakage of cytochrome c
into the cytosol (Figure 2). An apoptosome forms, consisting of cytochrome-c, Apaf-1 and
caspase 9, which activates caspase-3, the executioner of programmed cell death. The activa-
tion of the mitochondrial permeability transition pore (mPTP), a pathological membrane
protein complex, also increases the permeability of the mitochondria in response to Ca2+
influx [69]. Melatonin’s anti-apoptotic properties include activation of Bcl-2, which inhibits
Bax thereby preventing membrane permeabilization [70]. Melatonin also inhibits the open-
ing of the mPTP via receptor-dependent [71] and receptor independent mechanisms [72,73].
There is increasing evidence that sexual dimorphism exists in the mechanisms of cell death;
in females, cell death occurs primarily via a caspase-3 dependent pathway whereas in
males, who are more vulnerable to oxidative stress, caspase-independent, poly(ADP-ribose)
polymerase (PARP)-dependent pathways predominate [74]. The versatility of melatonin
also includes down-regulation of PARP protein expression [75].
2.4. Neuro-Inflammation
The inflammatory process following HI includes the release of cytokines, activation
of microglia, and the recruitment of peripheral immune cells [76]. In the piglet model,
cytokine (IL-1α, IL-6, CXCL-8, IL-10, TNFα) expression was upregulated following HI, with
and without prior inflammation-sensitisation [77] and serum IL-10 and IL-1β correlated
with MRS Lac/NAA peak area ratios [78]. Clinical studies also report associations between
cytokine levels in serum and CSF, severity of brain injury and neurodevelopmental out-
comes in infants with NE [79–81]. In response to HI, the release of extracellular ATP, free
radicals, and other damage associated molecular patterns (DAMPS) activate the Toll-like
receptor (TLR) family (TLR2, 3 and 4 most widely studied), which triggers intracellular
signalling pathways leading to NFkB translocation and gene transcription of inflammatory
cytokines and chemokines [76]. The P2X7 receptor is also activated by extracellular ATP,
resulting in microglial activation, NLRP3 inflammasome formation, caspase-1 activation
and IL-1β release [76]. Rodent studies using agents targeting the inflammatory signalling
cascade including IL-1 receptor inhibitor (IL1Ra) [82], candesartan, to reduce TLR2 ac-
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tivity [83] and TLR4 inhibitors [84] have been shown to be neuroprotective. Melatonin’s
neuroprotective action extends to immunomodulation; animal studies show melatonin sup-
presses NOS [85] and TLR4 expression [86] thereby inhibiting NFkB-dependent signalling.
Studies also report inhibition of NLRP3 inflammasome activation [87] although the effects
on neonatal HI models remain unknown. Whilst microglia have both pro-inflammatory
and reparative roles, in vitro and rodent studies suggest melatonin improves microglial
survival and attenuates the pro-inflammatory polarisation of microglia [88].
2.5. Receptor Mediated Neuroprotection
Rodent studies using Luzindole, an antagonist against the melatonin G protein recep-
tors MT1 and MT2, highlight a key role in the receptor-dependent action of melatonin [71].
The receptor targets of melatonin are diverse but include the widely expressed MT1 and
MT2 receptors, a cytosolic MT3 binding site identified as Quinolone Oxidoreductase 2
(NQO2) and the retinoid orphan receptor (ROR) family of nuclear receptors [89] (Figure 2).
The distribution of MT1 and MT2 receptors in the brain [90,91] appears to be discreet
and may suggest that they have divergent functions; Klosen et al. (2019) observed MT1
expression in the suprachiasmatic nucleus and pars tuberalis in the rodent brain whereas
MT2 expression was more widespread (including the forebrain, hippocampus, olfactory
bulb, amygdala and superior colliculus) [91]. The downstream targets remain unclear
but include gene transcription of antioxidant enzymes, regulation of synaptic plasticity,
neurogenesis, and regulation of cytochrome c release in mitochondria [92,93]. The de-
velopment of receptor specific ligands is needed to explore the functional differences in
receptors subtypes and potential mechanisms of neuroprotection. The role of NQO2 in
neuroprotection also remains controversial. Expression in the cortex, hippocampus, and
amygdala [94,95] have been reported. In an adult hamster model of neurodegeneration,
NQO2 activity was associated with oxidative stress and ROS induced cell death [96]. More
recently, several groups also report melatonin acts via α7 nicotinic acetylcholine receptors
to regulate autophagy and the inflammatory response [87,97].
3. Melatonin in Combination with Therapeutic Hypothermia
In high resource settings, HT is standard therapy for infants with moderate-severe NE
secondary to HI, therefore the assessment of neuroprotective interventions alongside HT is
necessary for such settings. Our key findings in the evaluation of melatonin in combination
with HT in the piglet model of perinatal HI are summarised in Table 1.
3.1. Safety
Over the last decade we have shown that melatonin infusion at rates of 5–10 mg/kg/h
(up to a total dose 30 mg/kg infused over 2 h) is safe and not associated with hypotension
in the piglet model. As melatonin is sparingly water soluble, excipients such as ethanol
are commonly used in preclinical studies [61,98,100,103] to obtain the desired highly
concentrated melatonin solution for intravenous use.
Initial pilot studies using Sigma-Aldrich melatonin, diluted in ethanol (2.5% v/v) given
intravenously at infusion rates ≥10 mg/kg/h was associated with hypotension requiring
0.9% saline boluses and inotropic support [98]. However, this was not observed in our
most recent study using the Chiesi ethanol-free melatonin formulation given intravenously
at 10 mg/kg/h [101]. It is unclear whether ethanol contributed to the observed fall in
blood pressure in the pilot studies; animal studies are conflicting. Adult ovine [104] and
rodent models of sepsis [105,106] report associations between high-dose 1 g/kg ethanol
administration and hypotension, mediated by the upregulation of NOS, and thereby,
smooth muscle relaxation, vasodilation, and reduced cardiac output. Conversely, low
dose 0.1 g/kg/h ethanol infusion, which more closely resembles ethanol concentrations
in our studies (~0.1 g/kg/h ethanol for 10 mg/kg/h melatonin-ethanol infusion), amelio-
rated septic shock in rats treated with Escherichia coli lipopolysaccharide [107]. Ethanol
vehicle infusion in the piglet [100] and sheep models [103] of NE do not report significant
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blood pressure differences. However, the cardiovascular effects of ethanol require careful
evaluation as following HI, haemodynamic instability is common and cerebrovascular
autoregulation is disrupted.
Table 1. Preclinical Studies Evaluating Melatonin Combined with Hypothermia for Neonatal Encephalopathy.
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Cytokine Signaling 3, SphK1 = Sphingosine kinase 1.
Whilst chronic foetal alcohol exposure and the resultant neurological sequelae are
well described [108], neonates receiving care in neonatal intensive care units are frequently
exposed, acutely, to drugs containing ethanol excipients [109]. As part of our melatonin
studies, we assessed the effects of ethanol excipient with and without melatonin in our
piglet model of perinatal asphyxia. Surprisingly [100], we observed protection from low
dose ethanol (0.28 g/kg) itself, observed as a reduction in TUNEL+ cell death in the white
matter and improved oligodendrocyte survival. The combination of melatonin with ethanol
provided significant neuroprotection and augmented HT. Indeed, neuroprotective effects
of ethanol have been reported in animal models of stroke [110–113]. Possible mechanisms
of neuroprotection include improved cerebral glucose metabolism through the inhibition
of hyperglycolysis, leading to a reduction in lactic acid accumulation and preservation of
energy (ATP) production [110]. Ethanol administration is also associated with reduction
in NADPH oxidase activity, resulting in reduced ROS production [110] and in apoptotic
protein expression [114].
The safety profile of melatonin doses of up to 30 mg/kg in ethanol [98,115] and
ethanol-free formulations [99,101] (Chiesi Int. pat. appl. PCT/EP2018/056423) have been
reassuring in our newborn piglet studies. However, there are several factors to be consid-
ered prior to the translation to first in human trials. As no licenced intravenous formulation
is available on the market to date, collaboration with pharmaceutical companies is needed
to expedite drug development. Melatonin is photosensitive and degrades rapidly within
hours of UV-A and UV-B exposure [116], necessitating specific storage and administra-
tion requirements. Excipient agents used to solubilise melatonin should complement the
neuroprotective action of melatonin and be safe for newborn use. Close attention to the
pharmacokinetic (PK) profile in babies with NE is also essential. In an open-label low dose
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melatonin PK study in preterm infants, the half-life of elimination was prolonged (15 h)
compared to adults (45–60 min) [117]. The group also noted considerable variation in drug
clearance and speculated immature liver function and poor renal excretion in premature
infants as contributing factors. Melatonin is metabolised by cytochrome P450 (CYP1A)
enzymes in the liver and excreted in the urine. Liver and renal impairment secondary
to HI may further impact melatonin elimination. Fortunately, pilot data reported that
HT does not affect the PK of melatonin in term infants [118]. As discussed below, the
therapeutic range of melatonin for neuroprotection from our preclinical studies is likely
between 15–30 mg/L. These levels are 10,000 times higher than plasma levels in newborns
at birth (typically ~80 pg/mL) [32]. The long-term consequences of supra-physiological
melatonin levels remains unknown. Reassuringly, doses of up to 70 mg/kg over 24 h given
to preterm infants for respiratory distress syndrome appeared safe in the short-term [119].
Jan et al. (2006) speculated that supplementary melatonin is unlikely to delay the onset of
pineal melatonin production in infants as endogenous melatonin production is enhanced,
rather than suppressed, in adults receiving melatonin therapy [120].
3.2. Efficacy and Therapeutic Levels
The efficacy data from four preclinical studies based on our three primary outcome
measures: aEEG, 1H MRS Lac/NAA and immunohistochemistry are shown in Table 1. The
pharmacokinetic profiles for these studies are shown in Figure 3.
In our first study, Robertson et al. (2013) [98], we observed significant augmentation
of HT protection with Sigma-Aldrich melatonin/ethanol administered at 10mins after HI.
Protection was based on improved aEEG recovery, improved thalamic cerebral energy
metabolism (Lac/NAA and NTP/EPP) and reduction in TUNEL positive cells in 4 brain
regions across the white and grey matter. Whilst isoprostane biomarkers were not signifi-
cantly different, gene expression for immunomodulation towards a deactivated microglia
phenotype (SOCS3, CD86 and SpK1) was observed. Melatonin levels of 17–31 mg/L were
achieved using 30 mg/kg Sigma-Aldrich melatonin/ethanol, started at 10 min after HI,
infused over 6h and repeated at 24 h (Figure 3). Based on these findings and in an in vitro
study [102], we estimate the therapeutic range to lie between 15–30 mg/L. The widespread
neuroprotection observed in this study is likely to be related to achieving therapeutic
melatonin levels early on after HI, thus utilizing the free-radical scavenging properties
of melatonin.
As administration of intravenous melatonin at 10 min is unlikely to be possible in the
clinical setting, we explored the effect of later administration. In our subsequent study,
Robertson et al., 2019 [99] administered melatonin at 2 h after HI using a slow 6 h infusion,
repeated at 26 h, in conjunction with a pre-clinical dose-escalating trial using the proprietary
Chiesi ethanol-free melatonin. Only partial protection was observed with the higher dose
of 15 mg/kg; localised reduction in TUNEL positive cells in the sensorimotor cortex was
reported but HT + melatonin did not confer improvement in aEEG background activity or
cerebral energy metabolism compared to HT alone. Whilst the absence of ethanol, shown
to be partially protective in Robertson et al. (2020) [100], may have contributed to the lack
of treatment benefit observed. Importantly, achievement of the Cmax (16.8 mg/L) was
delayed until ~8 h after HI (Figure 3). More rapid melatonin administration (18 mg/kg
over 2 h) in the Robertson et al., 2020 [100] study, achieving target therapeutic levels
(18.84 mg/L) earlier (within 3 h of HI), was associated with aEEG recovery from 19 h,
reduction in Lac/NAA peak ratios in the white matter and thalamus and overall reduction
in TUNEL positive cells compared to HT alone. Although the ethanol excipient likely
added to the neuroprotective action of the melatonin solution in this study [100], our
subsequent study (Pang et al. 2021) [101] using Chiesi melatonin at a higher dose of
20 mg/kg given over 2 h at 1 h after HI, repeated at 24 h and 48 h, augmented 12 h HT
in all three primary outcome measures. In HT + melatonin animals, cerebral background
aEEG recovery was more rapid from 25–30 h, Lac/NAA peak ratio reduced in the thalamus
at 66 h, and regional reduction in TUNEL positive cells in the sensorimotor cortex was
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observed compared to HT + vehicle. In the absence of the confounding effects of ethanol,
both studies using Chiesi melatonin [99,101] reported consistent localised protection in the
sensorimotor cortex, a region of high metabolic activity [121] and therefore, susceptible to
high levels of oxidative stress during energy failure in HI. The Cmax achieved was higher
(27.9 mg/L) and earlier (3 h) compared to the original Robertson et al., 2013 [98] study,
but trough levels prior to the second dose were lower (10 mg/L vs. 17 mg/L) (Figure 3).
Pharmacokinetic modelling using an escalated dose of 30 mg/kg over 2 h may increase the
area under the curve within, and maintain trough levels above, the putative 15–30 mg/L
therapeutic range.




Figure 3. Pharmacokinetic Profile of Sigma-Aldrich Melatonin dissolved in ethanol (a) and Chiesi ethanol-free melatonin 
(b). 
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supported by the impressive attenuation of •OH efflux following umbilical cord occlusion 
in the grey matter of foetal sheep by early pre-insult melatonin administration [54], sug-
gesting the antioxidative effect is likely key. 
Studies of other time-critical neuroprotective agents such as Xenon, although effica-
cious in preclinical studies [122,123], did not translate to added treatment benefit to cool-
ing in human trials [124,125], partly due to the delay of ~10 h before treatment could be 
started as babies needed to be transferred to xenon centres. Melatonin is easier to admin-
ister as an intravenous drug, mitigating unnecessary delays. However, combination ther-
apies with several neuroprotective interventions targeting the full spectrum of the neuro-
toxic cascade (Figure 1) may further improve outcomes. 
In our most recent study (Pang et al., 2021) [101], we assessed the safety and efficacy 
of combination therapy using erythropoietin (Epo) in addition to HT + melatonin (triple 
therapy). Epo is further along the translational pipeline, undergoing phase 3 clinical trials 
to assess its efficacy in combination with HT in babies with moderate to severe NE 
[126,127]. Its diverse mechanism of action includes not only antioxidant, anti-apoptotic, 
and anti-inflammatory properties, which complements melatonin, but also regenerative 
potential targeting the tertiary phase of injury. We observed that melatonin and Epo each 
augmented cooling alone, however the addition of Epo to HT + melatonin did not confer 
added neuroprotection in the short-term after 72 h. Unexpectedly, compared to HT + ve-
hicle, aEEG recovery was later at 55–60 h with triple therapy and the localised reduction 
in TUNEL positive cells in the sensorimotor cortex observed with HT + melatonin was 
lost. The reason for this early negative action of Epo therapy is unclear. It is possible that 
delayed Epo administration may be more beneficial, and longer-term studies are needed. 
There is also emerging evidence that melatonin enhances the therapeutic potential of 
stem cell therapies for traumatic brain injury, liver and cardiac disease, and sepsis [128]. 
In the piglet model of perinatal asphyxia, intranasal human mesenchymal stem cells 
(huMSC) augmented 12 h HT when targeted at the 24–48 h period following injury. Stem 
cells migrate to areas of injury and its neurotrophic response regulates cell death and neu-
roinflammation in the short term, and regeneration in the longer term. Interestingly, the 
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3.3. Further Optimisation: Combination Therapies
Although melatonin holds promise, our studies suggest the neuroprotective action of
melatonin is dose-dependent and ti e-critical; putative therapeutic levels f 15–30 mg/L
within 3 h of HI are r quired to harness its potent ntioxidant properties. This is upported
by the impressive attenuation of •OH efflux following umbilical cord occlusion n the grey
matter of foetal sheep by early pre-insult melatonin administration [54], suggesting the
a tioxidative eff ct is likely key.
Studi s of ther time-critical neuroprotective agents such as Xenon, although effica-
cious in preclinical studies [122,123], did not translate to added treatment benefit to cooling
in human trials [124,125], partly due to the delay of ~10 h before treatment could be started
as babies needed to be transferred to xenon centres. Melatonin is easier to ad inister as an
intravenous drug, mitigating unnecessary delays. However, combination therapies with
several neuroprotective interventions targeting the full spectrum of the neurotoxic cascade
(Figure 1) may further improve outcomes.
In our most recent study (Pang et al., 2021) [101], we assessed the safety and efficacy
of combination therapy using erythropoietin (Epo) in addition to HT + melatonin (triple
therapy). Epo is further along the translational pipeline, undergoing phase 3 clinical
trials to assess its efficacy in combination with HT in babies with moderate to severe
NE [126,127]. Its diverse mechanism of action includes not only antioxidant, anti-apoptotic,
and anti-inflammatory properties, which complements melatonin, but also regenerative
potential targeting the tertiary phase of injury. We observed that melatonin and Epo each
augmented cooling alone, however the addition of Epo to HT + melatonin did not confer
added neuroprotection in the short-term after 72 h. Unexpectedly, compared to HT +
vehicle, aEEG recovery was later at 55–60 h with triple therapy and the localised reduction
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in TUNEL positive cells in the sensorimotor cortex observed with HT + melatonin was
lost. The reason for this early negative action of Epo therapy is unclear. It is possible that
delayed Epo administration may be more beneficial, and longer-term studies are needed.
There is also emerging evidence that melatonin enhances the therapeutic potential of
stem cell therapies for traumatic brain injury, liver and cardiac disease, and sepsis [128].
In the piglet model of perinatal asphyxia, intranasal human mesenchymal stem cells
(huMSC) augmented 12 h HT when targeted at the 24–48 h period following injury. Stem
cells migrate to areas of injury and its neurotrophic response regulates cell death and
neuroinflammation in the short term, and regeneration in the longer term. Interestingly,
the antioxidant and anti-apoptotic properties of melatonin enhance the survival of stem
cells [129]. Pre-treatment with melatonin improved the “homing ability” of stem cells to the
site of injury [128]. Mesenchymal stem cells preconditioned with melatonin improved cell
survival under oxidative stress and oxygen-glucose deprivation conditions in vitro [130].
In the rodent stroke model, melatonin pre-treated MSC transplantation was associated
with reduction in apoptosis via an MT-receptor Erk1/2 dependent pathway [130]. The
neurotrophic effects (VEGF) and neurogenesis of MSCs were enhanced with melatonin
pre-treatment, resulting in improved neurobehavioral outcomes compared to animals who
received untreated-MSC [130]. Studies combining the effects of early melatonin as well as
“melatonin pre-treated stem cell therapies” in animal models of NE are now needed.
4. Melatonin as a Single Agent for the Low Resource Setting
As uncertainty remains in the safety and efficacy of HT in the low resource setting for
moderate to severe NE, there is an urgent need to identify alternative, simple neuroprotec-
tive interventions. Melatonin is a promising candidate to take through the translational
pipeline in such settings, given its diverse mechanisms of action and strong safety profile.
Outcomes from animal studies supporting the neuroprotective effects of melatonin as a
single agent for NE are compelling (Table 2). Thirteen studies [60,62,71,131–140] report
improvement in histological outcomes including reduction in infarct volume, reduction in
markers of apoptosis, necrosis, cell death, astrocytosis, and microgliosis. Neurobehavioral
studies were also reported in 3 studies [62,132,140], observing improved cognitive perfor-
mance, learning and memory, motor function, and co-ordination. Berger et al. (2019) [141]
reported no overall long-term treatment effect based on brain injury volume, diffusion
tensor imaging, histology and functional outcomes however the variability of injury in
this model was large. Subgroup analysis revealed fewer animals with severe injury in
the melatonin treated group compared to vehicle and the authors reported an absolute
risk reduction for severe injury of 38.7%. The authors speculated that the dosing regimen
(10 mg/kg IP given in the first day of life only; at 0 h, 6 h, and 25 h after HI) may have
contributed to the lack of long-term benefit. A key limitation in the rodent studies to
date is the absence of PK studies. As discussed in our piglet model, the neuroprotective
effect of melatonin is likely dose dependent. The half-life of melatonin is short in rats
(~20 min) and varies across animal species [142]. In the future, the inclusion of PK studies
is needed to ensure optimal drug dosing and inform researchers of target therapeutic
levels for future pre-clinical and human clinical trials. Care must also be taken in the
choice of the excipient used to solubilise melatonin. As observed, 9 of 16 studies used
5% dimethyl sulfoxide (DMSO) (Table 2). Whilst DMSO is used in clinical practice as a
cryopreservative for haematopoietic stem cell therapy [143], serious side-effects have been
reported including seizures, cardiac arrest, encephalopathy, cerebral infarction, respiratory
depression, severe neurotoxicity, and alternated consciousness [144]. Preclinical studies
using clinically acceptable excipients for use in high-risk infants are needed.
The route of administration and dosing regimen vary across the studies. Aridas and
colleagues [62] compared the efficacy of both intravenous and commercially available
transdermal melatonin patches in the sheep model of perinatal asphyxia. The transdermal
route is an attractive option in LMIC as patches are temperature stable; easy and quick to
apply, requiring minimal training; and non-invasive, minimising infection risk. Intriguingly,
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the authors observed improved neurobehavioral outcomes in both administration routes
and reduction in cleaved caspase-3 on immunohistochemistry. Although the transdermal
route shows promise, melatonin levels were 10-fold lower compared to the intravenous
route and levels were not sustained. The number of animals who received transdermal
melatonin were considerably smaller, and MRS outcomes were not available. A further
consideration to this route of administration is the requirement of significantly higher
doses to achieve the proposed 15–30 mg/L therapeutic levels. If it is feasible to develop
transdermal patches to achieve such levels, the risk of local skin reactions, which is a
known side-effect of transdermal melatonin may become a concern [145].
Table 2. Animal studies assessing melatonin as a single agent for neonatal encephalopathy.
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Table 2. Cont.
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LPS, then daily for 1 week
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Histology: melatonin improved
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Dose: 15 mg/kg IP, 1 h prior to
HI injury, then daily for 6 days
Excipient: 5% DMSO
Histology: reduced brain tissue
loss, inhibits neuronal apoptosis in
cortex




Dose: 10 mg/kg IP, immediately
after HI, single dose
Excipient: Not reported
Histology: Reduction in cerebral
oedema, reduction in glial cell
swelling and karyopyknosis and
interstitial tissue oedema.
Melatonin reduces mRNA
expression of oedema related
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and apoptosis with reduction in
BAX translocation and preserved











Dose: 10 mg/kg IP daily
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Dose: ~15 mg/kg IV, started at
30 min, given as 2 hourly 5 mg
boluses over 24 h
Excipient: absolute ethanol 2 mL
0.9% saline containing 3% Tween
(2) Transdermal patches
Dose 6 × 5 mg patches (total 30
mg) applied at 30 min, replaced
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PK: Intravenous: Cmax 150
ng/mL (~0.15 mg/L) at 4 h,
Transdermal: 27 ng/mL (~0.03
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Dose: 15 mg/kg IP, immediately
after HI, then 6h and 25 h after
Excipient: 5% DMSO
Imaging: Trend towards treatment
effect on Day 1 (tissue volume and
ADC) but lost at day 7, 20 and 43
Neurobehavioral: No treatment
effect
Histology: No treatment effect
No difference in
outcomes in sex
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Table 2. Cont.
Study Model Dosing and Excipient(Pharmacokinetics If Available) Outcomes Other Remarks




Dose: 10 mg/kg IP immediately
after HI, then every 24 h for 4
weeks
Excipient: Not reported
Histology: Reduction in infarct
volume
Neurobehavioral: Improved
performance in learning and
memory, motor function and











4HNE = 4-hydroxynonenal, ADC = Apparent diffusion coefficient, AQ4 = Aquaporin 4, DMSO = Dimethyl Sulfoxide, GFAP = Glial
fibrillary acidic protein, HI = hypoxia-ischaemia, IBA-1= Ionised calcium binding adaptor molecule 1, IP = intraperitoneal, SIRT 1 = Sirtuin 1,
IV = intravenous, ZO-1 = Zonula occludens-1.
There are some limitations of current animal models for NE in the LMIC setting.
Tann et al. [147] reported neonatal bacteriaemia and histological funisitis as significant
independent risk factors for NE in infants in Uganda. Infants born to mothers with
chorioamnionitis are at increased risk of long-term neurological sequalae [148]. In our
piglet model, LPS-sensitisation prior to HI was associated with increased severity of
brain injury [149]. Rodent studies suggest that the response to neuroprotective interven-
tions, following inflammation-sensitised HI, may be pathogen specific; HT to PAM3CSK4
(gram positive) sensitised-HI was protective [150], but HT exacerbated brain injury in LPS
sensitised-HI [151]. A further consideration is that current preclinical studies model an
acute intrapartum HI event. However, patterns of injury on early cranial ultrasound imag-
ing in Uganda suggest the onset of injury several hours before birth [152]. Predominant
white matter injury on MRI in an observation study of NE infants in India [153] may also
suggest a more chronic HI insult and/or exposure to perinatal inflammation. Preclinical
studies assessing the efficacy of neuroprotective interventions in the context of perinatal
inflammation and a more chronic, insidious onset of HI insults are needed.
5. Translating from Bench to Bedside
Although preclinical studies provide compelling evidence in the safety and efficacy of
melatonin as a neuroprotective agent, clinical studies are limited. Ahmed et al. [21] reported
a systematic review of clinical trials using melatonin as a single agent or in combination
with HT for NE. The systematic review highlighted the lack of large, well-designed, and
adequately powered randomised clinical trials in infants with NE [21] (Table 3).
To date, four of the five clinical trials [154–157] used the oral route of administration
with variable doses of: 10 mg once only [156], every 2 h for 4 doses [154], or 10 mg/kg
daily for 5 days [155,157] but the pharmacokinetic profiles in all studies were not reported.
The oral bioavailability is less certain in newborns due to higher gastric pH, lower superior
mesenteric arterial blood flow and delayed gastric emptying [158]. In adults, the absolute
oral bioavailability of melatonin has been reported to be 15% [159]. Carloni et al. [160]
observed serum melatonin levels of 7 mg/L were achievable with 5 mg/kg oral adminis-
tration in preterm infants however, with a delay of 4 h to reach Cmax. The reduction in
gastro-intestinal blood flow [161] and impaired gastrointestinal peristalsis, associated with
infants with NE [162], will most likely impact the oral bioavailability of melatonin further.
Given the narrow therapeutic window of melatonin, the intravenous route is the preferred
route, as it provides the most predictable levels required for neuroprotection, bypassing the
gastro-intestinal effects post HI and first passes metabolism in the liver. Neuroprotective
agents given via the intranasal route has also received some interest [115] as it provides a
more direct and rapid pathway to the brain, via the olfactory nerve and cribriform plate.
Whilst this may reduce the melatonin dosing requirements and, therefore, exposure to
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the neurotoxic excipients, Van den Berg and colleagues [163] showed melatonin uptake in
the CSF were similar between the intranasal and intravenous route. Highly concentrated
melatonin formulations would be required to deliver therapeutic levels.
In the clinical melatonin trials, clinically relevant outcome measures were underre-
ported; Aly et al. [155] observed improved survival without disability, albeit at 6 months,
and Jerez-Calero et al. [164] showed improved cognitive outcomes on Bayley III neurode-
velopmental assessment at 18 months in infants who received melatonin in combination
with HT compared to HT alone, however the study was confounded by small sample size
and a trend towards lower NE severity in the melatonin group. Consideration in future
clinical design should also include surrogate biomarkers for outcomes in NE to accelerate
clinical trials. 1H MRS Lac/NAA peak ratio has been validated in both preclinical [46]
and clinical studies [44,124]. Using a Lac/NAA threshold value of 0.39, BGT Lac/NAA
predicted 2-year neurodevelopment outcomes with high accuracy in infants who received
HT for NE [44]. The TOBY-Xenon clinical trial, powered to detect a difference in the MRS
Lac/NAA peak area ratio, recruited babies in January 2012 over 18 months, publishing in
2016 no biological effect based on difference in Lac/NAA (geometric mean difference of
1.09 (95% CI 0.9–1.32)) [125]. Follow-up neurodevelopmental data at 2–3 years of age in
2019 showed that Lac/NAA accurately predicted adverse outcomes in 96% of cases [124].
Table 3. Randomised clinical trials using melatonin for neonatal encephalopathy in infants and relevant clinical outcomes.
Study Population Intervention Comparison Clinical Outcomes















Mortality: RR 0.14 (95% CI 0.01–2.45)
Imaging: Not reported
Neurodevelopment: Not reported
















Mortality: RR 0.25 (95% CI 0.03, 1.98)
EEG: melatonin had fewer seizures
(3/14 in HT + melatonin vs. 7/11 in
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Imaging: MRI–less white matter
abnormalities (0/14 in HT + melatonin
vs. 4/11 in HT)
Neurodevelopment: Improved
survival without abnormalities at
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HIE: Apgar score < 5
at 5 min,
Cord pH < 7 and/or



















(Apgar < 5 at 5 min,
Cord pH < 7 and/or
BE ≤ −16,
Moderate-severe NE
(Sarnat score ≥ 6)
N = 12
HT + Melatonin
Dose: 5 mg/kg within 6 h of
birth, over 2 h, daily for 3 days
Route: IV







Mortality: RR 1.0 (95% CI 0.07, 14.21)
aEEG: No difference in background
activity or seizure burden
Imaging: No difference in MRI
outcomes
Neurodevelopment: Improved
cognitive composite score (p = 0.05) at
18 months on Bayley III Test, no other
significant differences
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As we move towards translating melatonin from bench to bedside, several challenges
remain in the drug development of suitable intravenous melatonin formulation prior
to clinical trials. In general, any product used for clinical or therapeutic use should be
produced to Good Manufacturing Practice (GMP); a regulation to ensure that the product is
reproduceable and manufactured in a controlled environment. As the prevalence of NE is
<1 in 2000 people, it is classified by the European Medicines Agency (EMA) as a rare disease,
therefore eligible for Orphan Drug Designation (ODD). ODD supports pharmaceuticals by
attracting investment when it is perceived that the commercial market is relatively small
or the intellectual property surrounding the therapy is limited. In Europe, EMA provides
access to the EMA central authorisation procedure and 10 years market exclusivity. The
United States Food and Drug Administration (FDA) provide a comprehensive package
including tax credits of up to 50% off the clinical drug testing cost awarded upon approval,
fee waivers new drug application (NDA) or biologic licence applications (BLA) and 7 years
market exclusivity.
6. Conclusions
The preclinical data for melatonin as a neuroprotective agent for NE is compelling. In
our piglet model, we have shown, over several studies, that melatonin is safe and augments
the neuroprotective benefit of cooling. Whilst promising, to the best of our knowledge,
no other in-vivo animal studies have assessed the efficacy of melatonin in combination
with HT. Our studies are limited to 48–72 h in duration, and longer-term studies to assess
the neurobehavioral outcomes would further support our findings. Nonetheless, a key
strength to our model is the use clinical outcomes such as aEEG and magnetic resonance
spectroscopy Lac/NAA which are validated outcome biomarkers to predict neurodevelop-
mental outcomes in babies with NE. Other preclinical studies using melatonin as a single
agent support its neuroprotective efficacy in NE.
The mechanism of action of melatonin is diverse, but for optimal effect, melatonin’s
antioxidant properties must be harnessed early in the neurotoxic cascade. Long-term effects
of supra-physiological melatonin levels on the developing brain remains unknown. The
reassuring physiological profile seen with high dose melatonin over the critical first 3 days
of treatment in our pre-clinical models is encouraging. Infants with moderate to severe
NE are at risk of significant mortality and morbidity; the time is now right for exploring
melatonin in clinical neuroprotection trials.
Whilst the evidence for single agent melatonin therapy in preclinical animal studies of
NE is valid, further studies in the context of inflammation-sensation and chronic HI are
needed for the LMIC setting. The feasibility of intravenous administration and additional
requirements, given the photosensitive nature of melatonin, should also be considered
in this context. Robust PK studies are needed to establish the effect of HI on melatonin
clearance in term infants.
The development of intravenous melatonin formulations with safe excipients (which
may themselves be partially protective e.g., ethanol) for clinical use remains a key limit-
ing step requiring the collaboration of neuroscientists, clinicians, pharmaceuticals, and
research councils. In parallel, further preclinical studies are needed to identify a bundle
of complementary neuroprotective agents and interventions targeting every aspect of
the neurotoxic cascade to maximise the potential to change the trajectory of brain injury
following perinatal HI. Agents targeting neuro-regeneration and repair (such as delayed
Epo and stem-cells) to complement early melatonin administration holds promise and
warrants further assessment in large recovery animal models.
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